RGCC

Across TCGA pan-cancer cohorts, RGCC Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RGCC data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RGCC Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RGCC expression acts as an unfavorable survival marker.

BLCA and COAD are the cancer types where RGCC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.117	0.720	<.001	36	view →
COAD	OS	Median	All	0.001	0.871	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RGCC–BLCA (OS)

Open the BLCA breakdown →